Under construction – not a live service
Sign in
Not yet recruitingNo phase

Walking for Hypothyroidism Trial (WHT)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 55 years old?

Source: NCT07205042, who can take part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
University of Karachi
Trial code
NCT07205042
Record updated
3 October 2025
Original description
Women with hypothyroidism often report persistent fatigue, weight gain, autonomic dysregulation, and stress despite stable levothyroxine therapy. This single-center, parallel-group RCT will test whether a structured, supervised 12-week walking program improves basal metabolic rate (BMR) and psychophysiological outcomes compared with usual activity. One hundred twenty women aged 35-55 with stable primary hypothyroidism will be randomized 1:1 to intervention or control.Read full original descriptionShow less

A Randomized Controlled Trial of a 12-Week Walking Program on Metabolic and Psychophysiological Outcomes in Women With Hypothyroidism

Women with hypothyroidism often report persistent fatigue, weight gain, autonomic dysregulation, and stress despite stable levothyroxine therapy. This single-center, parallel-group RCT will test whether a structured, supervised 12-week walking program improves basal metabolic rate (BMR) and psychophysiological outcomes compared with usual activity. One hundred twenty women aged 35-55 with stable primary hypothyroidism will be randomized 1:1 to intervention or control.

Inclusion: Female, aged 35-55 years; Primary hypothyroidism with documented prior TSH >4.5 mIU/L; Stable levothyroxine dose for at least 6 months; Sedentary lifestyle (<150 minutes of moderate-vigorous activity per week); BMI between 20-35 kg/m²; Able to walk unaided; Willing and able to provide written informed consent.

Exclusion: Use of beta-blockers, systemic corticosteroids, or medications significantly affecting heart rate, HRV, or metabolism; Uncontrolled hypertension, insulin-dependent diabetes, symptomatic cardiovascular disease, or orthopedic conditions limiting walking; Major psychiatric hospitalization in the past 12 months; Pregnant or lactating, or planning pregnancy during the study period; Participation in another interventional trial within the past 30 days.

ClinicalTrials.gov NCT07205042